157 related articles for article (PubMed ID: 15106741)
1. [Inadequate management of dyslipidaemic patients in France. Results of the Odyssée study].
Ferrières J; Elbaz M; Maupas E; Carriè D; Puel J
Arch Mal Coeur Vaiss; 2004 Mar; 97(3):187-93. PubMed ID: 15106741
[TBL] [Abstract][Full Text] [Related]
2. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM
Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
[TBL] [Abstract][Full Text] [Related]
3. [Achieving the target lipid levels in Hungary, 2004].
Márk L; Zámolyi K; Pados G; Paragh G; Ofner P
Orv Hetil; 2005 Jan; 146(4):147-52. PubMed ID: 15751508
[TBL] [Abstract][Full Text] [Related]
4. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
5. [Biochemical evaluation of the results of lipid regulating treatment in France].
Ferrières J; Lablanche JM; Pouchain D; Girerd X; Krempf M; Nguyen G; Glanddier PY
Arch Mal Coeur Vaiss; 2005 Jan; 98(1):58-62. PubMed ID: 15724421
[TBL] [Abstract][Full Text] [Related]
6. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML
Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967
[TBL] [Abstract][Full Text] [Related]
7. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting.
Mosca L; Merz NB; Blumenthal RS; Cziraky MJ; Fabunmi RP; Sarawate C; Watson KE; Willey VJ; Stanek EJ
Circulation; 2005 Feb; 111(4):488-93. PubMed ID: 15687138
[TBL] [Abstract][Full Text] [Related]
8. Achieving vascular risk factor targets: a survey of a London general practice.
Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
[TBL] [Abstract][Full Text] [Related]
9. [Treatment with statins in general medicine: dosage and effectiveness. Results of the observational study STATIMED].
Amouyel P; Lamarque H; Gayet JL
Arch Mal Coeur Vaiss; 2005 Dec; 98(12):1206-11. PubMed ID: 16435599
[TBL] [Abstract][Full Text] [Related]
10. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
[TBL] [Abstract][Full Text] [Related]
11. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
12. 5-year evaluation of electronic medical record flag alerts for patients warranting secondary prevention of coronary heart disease.
Whitley HP; Fermo JD; Chumney EC
Pharmacotherapy; 2006 May; 26(5):682-8. PubMed ID: 16637797
[TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
Portolés J; López-Gómez JM; Aljama P
Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
[TBL] [Abstract][Full Text] [Related]
14. [Lipiwatch: a study of the treatment of dyslipidemias in Luxembourg].
Michel G; Wirion R; Keipes M; Scharpantgen R; Heger G;
Bull Soc Sci Med Grand Duche Luxemb; 2001; (1):29-36. PubMed ID: 11570211
[TBL] [Abstract][Full Text] [Related]
15. [Quality of therapeutic control of hyperlipidemias in secondary prevention of coronary heart disease in the light of current recommendations].
Mayer O; Mayer O
Vnitr Lek; 2004 Oct; 50(10):777-80. PubMed ID: 15633934
[TBL] [Abstract][Full Text] [Related]
16. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
17. Is the treatment of hyperlipidemia as secondary prevention adequate in different age groups in Israel?
Shilo L; Feldman J; Gendlman V; Shenkman L; Berner YN
Isr Med Assoc J; 2003 Jul; 5(7):479-81. PubMed ID: 12901241
[TBL] [Abstract][Full Text] [Related]
18. Coronary risk estimates and decisions on lipid-lowering treatment in primary prevention: comparison between general practitioners, internists, and cardiologists.
Vancheri F; Strender LE; Montgomery H; Skånér Y; Backlund LG
Eur J Intern Med; 2009 Oct; 20(6):601-6. PubMed ID: 19782921
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
Petrella RJ; Merikle E; Jones J
Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
